Improve human health by unlocking the power of hyperspectral imaging and machine learning
Improve human health by unlocking the power of hyperspectral imaging and machine learning
Changing the treatment paradigm to allow intervention when damage is minimal
There is a large potential for oculomics to detect major diseases at their earliest stages and provide a path to earlier intervention before damage is significant.
Cardiovascular Diseases
Aneurysm Giant Cell Arteritis High Blood Pressure
High Cholesterol Stroke Vascular Disease
Neurological Diseases
Aneurysm Giant Cell Arteritis High Blood Pressure
High Cholesterol Stroke Vascular Disease
Cancers and Blood Disorders
Cancers of Tissue or Skin Sickle Cell Disease
Leukemia or Lymphoma
Metabolic and Endocrine Disorders
Diabetes Thyroid Disease
High Cholesterol Vitamin A Deficiency
Autoimmune Diseases
Lupus Rheumatoid Arthritis
Sarcoidosis Sjögren's Syndrome
Infectious Diseases & Other
Lyme Disease Sexually Transmitted Diseases
Medication Toxicities
Your eyes are the window to your health
The retina is a layer of cells at the back of the eye that converts light into nerve signals. It serves as an extension of the brain and is enclosed within the blood-brain barrier. It is the only part of the body that provides direct visualization of both neurological and cardiovascular systems.
About us
We are pioneers in the discovery and utilization of ophthalmic biomarkers to transform the patient journey
We empower pharmaceutical innovation by streamlining patient enrollment, shortening study timelines, and reducing costs
Patient enrollment is time-consuming and costly. In Alzheimer’s disease drug trials, biomarker-based patient screening prior to amyloid PET scans could reduce trial duration by 49% and save over 40% in costs.
We improve patient outcomes by enabling intervention when the irreversible damage is minimal
Amyloid plaque accumulates over a decade, causing irreversible brain tissue damage
Symptom Development
Early cognitive symptoms are often mistaken for normal aging, further delaying treatment
Diagnosis
Health Deterioration
Undiagnosed AD leads to life threatening comorbidities, rapid decline in quality of life
Diagnosis
Onset of Disease
Our technology is convenient, cost-effective, and non-invasive, making it ideal for large-scale population screening to detect patients in the earliest stages of disease, when brain damage is minimal.
Symptom Development
Early detection enables proactive management of risk factors and eligibility for novel disease-modifying therapies, helping to delay symptom onset and preserve quality of life
Health Deterioration
Undiagnosed AD leads to life threatening comorbidities, rapid decline in quality of life
Amyloid plaque accumulates over a decade, causing irreversible brain tissue damage
Symptom Development
Early cognitive symptoms are often mistaken for normal aging, further delaying treatment
Diagnosis
Diagnosis
Diagnosis
Health Deterioration
Undiagnosed AD leads to life threatening comorbidities, rapid decline in quality of life
Onset of Disease
Our technology is convenient, cost-effective, and non-invasive, making it ideal for large-scale population screening to detect patients in the earliest stages of disease, when brain damage is minimal.
Diagnosis
Symptom Development
Early detection enables proactive management of risk factors and eligibility for novel disease-modifying therapies, helping to delay symptom onset and preserve quality of life
Diagnosis
Diagnosis
Health Deterioration
Undiagnosed AD leads to life threatening comorbidities, rapid decline in quality of life
Plaque accumulates over 10-years before symptoms emerge,causing irreversible disease progression
Symptom Development
Symptoms begins with subtle cognitive changes that often mistaken for normal aging. Diagnosis is invasive and inaccessible
Disease Progression
Alzheimer’s progresses rapidly,leading to major health crisis that necessitate expensive interventions and full-time care
Onset of Disease
Routine screening detects at-riskpatients, initiating preventative and therapeutics treatment
Typical Diagnosis post-OptoIntel
-
Hyperspectral retinal imaging could detect brain β-amyloid status with ≥85% accuracy 1
Symptom Development
Early treatment could slow down Alzheimer’s disease progression by 30+%2
Typical Diagnosis pre-OptoIntel
Disease Progression
Our focus
We initially focus on neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and ALS, which collectively affect over 50 million people worldwide.
Currently, there is no cure for these conditions, and available treatments offer only limited options to delay progression. The insidious nature of these diseases often leads to irreversible brain damage, rendering treatments ineffective once symptoms become apparent.
We look forward to expanding our focus to include cardiovascular and renal diseases.
